Allient (ALNT) Competitors $21.35 -0.27 (-1.25%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALNT vs. TXG, TRNS, CTKB, SENS, EYPT, LAB, AEHR, QTRX, QSI, and MASSShould you be buying Allient stock or one of its competitors? The main competitors of Allient include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), Senseonics (SENS), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Quanterix (QTRX), Quantum-Si (QSI), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Allient vs. 10x Genomics Transcat Cytek Biosciences Senseonics EyePoint Pharmaceuticals Standard BioTools Aehr Test Systems Quanterix Quantum-Si 908 Devices 10x Genomics (NASDAQ:TXG) and Allient (NASDAQ:ALNT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking. Is TXG or ALNT more profitable? Allient has a net margin of 2.64% compared to 10x Genomics' net margin of -29.90%. Allient's return on equity of 10.80% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-29.90% -25.40% -19.69% Allient 2.64%10.80%4.75% Does the media refer more to TXG or ALNT? In the previous week, 10x Genomics had 1 more articles in the media than Allient. MarketBeat recorded 8 mentions for 10x Genomics and 7 mentions for Allient. 10x Genomics' average media sentiment score of 1.30 beat Allient's score of 0.55 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allient 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, TXG or ALNT? 10x Genomics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Allient has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Which has higher valuation and earnings, TXG or ALNT? Allient has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.79M1.66-$182.63M-$1.52-5.44Allient$529.97M0.68$24.10M$0.8026.69 Does the MarketBeat Community believe in TXG or ALNT? 10x Genomics received 56 more outperform votes than Allient when rated by MarketBeat users. However, 75.00% of users gave Allient an outperform vote while only 50.82% of users gave 10x Genomics an outperform vote. CompanyUnderperformOutperform10x GenomicsOutperform Votes6250.82% Underperform Votes6049.18% AllientOutperform Votes675.00% Underperform Votes225.00% Do institutionals and insiders hold more shares of TXG or ALNT? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 61.6% of Allient shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by company insiders. Comparatively, 15.6% of Allient shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend TXG or ALNT? 10x Genomics currently has a consensus price target of $18.85, indicating a potential upside of 127.89%. Allient has a consensus price target of $31.00, indicating a potential upside of 45.20%. Given 10x Genomics' higher possible upside, research analysts plainly believe 10x Genomics is more favorable than Allient.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38Allient 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryAllient beats 10x Genomics on 10 of the 19 factors compared between the two stocks. Get Allient News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNT vs. The Competition Export to ExcelMetricAllientInstruments to measure electricity IndustryComputer SectorNASDAQ ExchangeMarket Cap$366.42M$3.93B$23.05B$7.83BDividend Yield0.56%0.55%2.97%4.22%P/E Ratio24.2620.2042.1318.48Price / Sales0.682.302,148.23103.59Price / Cash6.8617.8734.7234.62Price / Book1.383.146.134.25Net Income$24.10M$135.28M$738.82M$248.23M7 Day Performance-1.20%-0.30%1.31%0.89%1 Month Performance-2.95%1.86%1.65%3.53%1 Year Performance-27.43%-9.99%52,744.84%5.08% Allient Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNTAllient3.9888 of 5 stars$21.35-1.2%$31.00+45.2%-27.4%$366.42M$529.97M24.261,950Upcoming EarningsShort Interest ↑TXG10x Genomics4.6638 of 5 stars$8.48+2.2%$19.79+133.3%-71.8%$1.04B$610.79M-5.581,240Upcoming EarningsNews CoveragePositive NewsGap DownTRNSTranscat2.2519 of 5 stars$80.98-4.9%$111.50+37.7%-26.1%$753.84M$272.20M43.77920Positive NewsCTKBCytek Biosciences2.5796 of 5 stars$3.86+2.4%$6.42+66.2%-38.3%$494.45M$200.45M-48.24500Upcoming EarningsPositive NewsSENSSenseonics1.7367 of 5 stars$0.72-4.4%$2.00+177.2%+52.9%$472.08M$22.47M-5.5590News CoverageEYPTEyePoint Pharmaceuticals1.7176 of 5 stars$6.78+6.4%$26.63+292.7%-61.3%$465.98M$43.27M-3.39120Upcoming EarningsNews CoveragePositive NewsLABStandard BioTools2.8585 of 5 stars$1.18+1.7%$2.50+111.9%-55.2%$447.20M$174.43M-1.66620Upcoming EarningsNews CoverageAEHRAehr Test Systems3.6187 of 5 stars$8.70-0.7%$25.00+187.4%-28.8%$259.01M$61.48M11.6090Positive NewsQTRXQuanterix2.4618 of 5 stars$5.78-1.7%$18.25+215.7%-64.3%$224.20M$135.44M-5.45460Upcoming EarningsAnalyst ForecastNews CoverageQSIQuantum-Si2.419 of 5 stars$1.21-1.6%$3.48+187.2%-29.2%$221.60M$3.06M-1.89150News CoverageGap DownMASS908 Devices1.1632 of 5 stars$5.33-1.5%$5.33+0.1%-4.7%$188.31M$59.63M-3.0160News CoverageGap Down Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Cytek Biosciences Alternatives Senseonics Alternatives EyePoint Pharmaceuticals Alternatives Standard BioTools Alternatives Aehr Test Systems Alternatives Quanterix Alternatives Quantum-Si Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allient Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allient With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALNT Stock Free ALNT Stock Alerts